Q4 2023 · 13F-HR
Blue Owl Capital Holdings LPholdings as filed
Filed 2024-02-15 · accession 0000950123-24-002647
$418.3M
Reported value
43
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $54.4M | 13.0% | 3,004,199 | Common | SOLE |
| 770700102 | HOOD | ROBINHOOD MKTS INC | $54.0M | 12.9% | 4,237,409 | Common | SOLE |
| 230031106 | CGEM | CULLINAN ONCOLOGY INC | $34.8M | 8.33% | 3,419,842 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $32.4M | 7.74% | 1,332,302 | Common | SOLE |
| 49845K101 | KVYO | KLAVIYO INC | $31.5M | 7.52% | 1,198,270 | Common | SOLE |
| 69121K104 | OBDC | BLUE OWL CAPITAL CORPORATION | $30.2M | 7.22% | 2,045,070 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $22.8M | 5.45% | 3,122,499 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $17.1M | 4.09% | 2,292,990 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $15.5M | 3.71% | 3,414,468 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $14.0M | 3.35% | 352,633 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $12.6M | 3.01% | 263,238 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $11.4M | 2.72% | 1,234,760 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $8.5M | 2.02% | 1,493,252 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $8.1M | 1.94% | 140,260 | Common | SOLE |
| 29788T103 | ETWOGBP | E2OPEN PARENT HOLDINGS INC | $7.2M | 1.73% | 1,650,943 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $6.6M | 1.59% | 71,888 | Common | SOLE |
| 888787108 | TOST | TOAST INC | $6.0M | 1.44% | 5,890,274 | Common | SOLE |
| 45790W108 | — | INOZYME PHARMA INC | $5.4M | 1.29% | 1,270,027 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $4.9M | 1.17% | 568,379 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $4.4M | 1.06% | 2,829,712 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $3.9M | 0.94% | 65,000 | Common | SOLE |
| 45175G108 | — | IKENA ONCOLOGY INC | $3.8M | 0.92% | 1,953,616 | Common | SOLE |
| 25460G716 | LABDUSD | DIREXION SHS ETF TR | $3.3M | 0.79% | 340,000 | Common | SOLE |
| 68217N105 | — | OMEGA THERAPEUTICS INC | $3.2M | 0.76% | 1,055,882 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $2.8M | 0.67% | 864,822 | Common | SOLE |
| 24703L202 | DELL | DELL TECHNOLOGIES INC | $2.7M | 0.64% | 35,091 | Common | SOLE |
| 68570P200 | — | ORCHARD THERAPEUTICS PLC | $2.6M | 0.63% | 1,599,660 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $2.5M | 0.60% | 60,000 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS I | $2.0M | 0.47% | 695,000 | Common | SOLE |
| 786700104 | SGMT | SAGIMET BIOSCIENCES INC | $1.9M | 0.46% | 355,377 | Common | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $1.2M | 0.29% | 733,568 | Common | SOLE |
| 38046W204 | GOCO | GOHEALTH INC | $1.1M | 0.27% | 83,264 | Common | SOLE |
| 10576N102 | BRZE | BRAZE INC | $941,782 | 0.23% | 17,726 | Common | SOLE |
| 09352U108 | BLND | BLEND LABS INC | $922,052 | 0.22% | 361,587 | Common | SOLE |
| 75120L100 | — | RALLYBIO CORP | $837,074 | 0.20% | 350,240 | Common | SOLE |
| 25058X105 | — | DESKTOP METAL INC | $563,250 | 0.13% | 750,000 | Common | SOLE |
| 35655L206 | — | FREELINE THERAPEUTICS HLDGS | $551,986 | 0.13% | 86,654 | Common | SOLE |
| 29286M113 | — | ENGENE HOLDINGS INC | $403,815 | 0.10% | 475,077 | Common | SOLE |
| 90353T100 | UBER | UBER TECHNOLOGIES INC | $380,934 | 0.09% | 6,187 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $295,584 | 0.07% | 10,013 | Common | SOLE |
| 31189Y103 | — | FATHOM DIGITAL MFG CORP | $222,915 | 0.05% | 50,000 | Common | SOLE |
| 74019P108 | — | PRECISION BIOSCIENCES INC | $221,420 | 0.05% | 606,629 | Common | SOLE |
| G63290103 | PLMWF | ALPHA PARTNERS TECH MERGR CO | $0 | — | 666,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.